National Institutes of Health, a Component of the US Dept. of Health & Human Services

University of Minnesota

Intima Bioscience, Inc.

The United States of America As Represented by the Department of Health

Mount Sinai School of Medicine

Kite Pharma, Inc.

The Government of the United States of America, As Represented by the

Nicholas P Restifo

Steven A Rosenberg

Branden Moriarity

Beau R Webber

Modassir Choudhry

Douglas C Palmer

Zhiya Yu

R Scott McIvor

Igor Bacik

Lydie Cassard

Jonathan W Yewdell

Raul E Vizcardo

David Largaespada

Mario Roederer

Luca Gattinoni

Jack R Bennink

Enrico Lugli

Peter M Palese

Adolfo Garcia-Sastre

Richard A Morgan

Ling Zhang

Marianna Sabatino

Arianne Perez

Jack R Bennick

Meghan L Good

Naritaka Tamaoki

Robert L Eil

Rigel J Kishton

Nicholas D Klemen

Shashankkumar J Patel

Suman Kumar Vodnala

Scott R Mcivor

Provided are methods of producing an isolated population of T cells, the method comprising culturing isolated T cells in vitro in the presence of hydroxycitric acid, and/or a salt thereof, wherein the salt is potassium hydroxycitrate or sodium hydroxycitrate. Also provided are related isolated populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer in a mammal.

Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof

Disclosed are methods of preparing thymic emigrant cells in vitro, isolated or purified thymic emigrant cells prepared by the methods, and pharmaceutical compositions comprising the same. Further disclosed are methods of treating or preventing a condition in a mammal comprising administering the thymic emigrant cells or pharmaceutical compositions comprising the same to the mammal.

Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same

Disclosed are methods of preparing CD34+CD43+ hematopoietic progenitor cells (HPC) in vitro according to embodiments of the invention. Also disclosed are methods of differentiating CD34+CD43+ hematopoietic progenitor cells to hematopoietic lineage cells according to embodiments of the invention. Also disclosed are methods of treating or preventing a condition in a mammal, e.g., cancer, according to embodiments of the invention.

Methods of preparing hematopoietic progenitor cells in vitro

Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.

Intracellular genomic transplant and methods of therapy

Disclosed are methods of preparing thymic organoids according to embodiments of the invention. Also disclosed are methods of preparing thymic emigrant cells in vitro, according to embodiments of the invention. Also disclosed are methods of treating or preventing a condition in a mammal, e g., cancer.

In vitro generation of thymic organoid from human pluripotent stem cells

Provided herein are methods for delaying or inhibiting T cell maturation or differentiation in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation. In some embodiments, the method further comprises administering the one or more T cells to a subject in need of a T cell therapy.

Methods of preparing T cells for T cell therapy

Modified cells and methods of therapy

Disclosed are methods of selecting a therapy for a cancer patient and methods of treating cancer in the patient. The methods comprise detecting a mutation in one or more genes in a cancer cell from the patient, wherein the one or more genes is selected from the group consisting of PTCD2, TWF1, DEFB134, BBS1, SOX10, APLNR, CD58, COL17A1, CRKL, hsa-mir-101-2, hsa-mir-548s, MAD2L1, MLANA, PSMB5, RNPS1, RPL10A, RPL23, SRP54, TAF3, TAP1, TAP2, TAPBP, TBXAS1, GMIP, OTOA, LAIR1, CLEC1, GPSM3, TRAF1, JAK2, TAPBPL, ICAM1, LILRA1, LILRA3, STAT1, and HLA-F. Also disclosed are methods of screening for one or more genes, the mutation of which confers resistance to T cell-mediated cytolytic activity.

Methods for selecting therapy for a cancer patient

Genetically modified compositions, such as non-viral vectors and tumor infiltrating lymphocytes, for the treatment of gastrointestinal cancer are disclosed. Disclosed are methods of utilizing a CRISPR system to generate genetically modified compositions. Also disclosed are the methods of making and using the genetically modified compositions for the treatment of gastrointestinal cancer.

Tumor infiltrating lymphocytes and methods of therapy

Provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating na&#xef;ve T cells from a mammal, wherein the mammal is not a mouse; b) activating the na&#xef;ve T cells and expanding the numbers of na&#xef;ve T cells in the presence of one or more non-specific T cell stimuli, one or more cytokines, and a GSK-3beta inhibitor. Also provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating lymphocytes from a mammal; b) sorting the lymphocytes using flow cytometry into a population comprising a phenotype comprising i) CD95+, CD45RO&#x2212;, and CCR7+; and ii) CD62L+ or one or more of CD27+, CD28+, CD45RA+, and CD127+ to produce an isolated T memory stem cell population. Further embodiments of the invention provide related cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.

Methods of producing T memory stem cell populations

Growing community of inventors

Chevy Chase, MD, United States of America

Nicholas P Restifo